CA2191655A1 - Novel antibody compositions for preparing enriched human hematopoietic and tumor cell preparations - Google Patents

Novel antibody compositions for preparing enriched human hematopoietic and tumor cell preparations

Info

Publication number
CA2191655A1
CA2191655A1 CA002191655A CA2191655A CA2191655A1 CA 2191655 A1 CA2191655 A1 CA 2191655A1 CA 002191655 A CA002191655 A CA 002191655A CA 2191655 A CA2191655 A CA 2191655A CA 2191655 A1 CA2191655 A1 CA 2191655A1
Authority
CA
Canada
Prior art keywords
antibodies
antibody composition
cd66b
glycophorin
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002191655A
Other languages
French (fr)
Other versions
CA2191655C (en
Inventor
Terry E. Thomas
Peter M. Lansdorp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
StemCell Technologies Inc
Original Assignee
StemCell Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/566,295 external-priority patent/US6306575B1/en
Application filed by StemCell Technologies Inc filed Critical StemCell Technologies Inc
Publication of CA2191655A1 publication Critical patent/CA2191655A1/en
Application granted granted Critical
Publication of CA2191655C publication Critical patent/CA2191655C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to an antibody composition which contains antibodies specific for glycophorin A, CD3, CD24, CD16, CD14, and optionally CD45RA, CD38, CD36, CD38, CD56, CD2, CD19, CD66e, CD66b, and antibodies specific for antigens expressed on non-hematopoietic tumor cells.
A process is provided for enriching and recovering human hematopoietic progenitor cells and stem cells in a sample containing human hematopoietic differentiated, progenitor, and stem cells, and tumor cells.
The invention also contemplates tumor-enriching antibody compositions containing antibodies to glycophorin A, CD3, CD19, CD36, CD14, CD16, CD66b, CD66e, CD38, and optionally CD45, CD41, CD33, CD20, CD22, CD29, CD2, CD45RA, and/or CD10 and a process for enriching for metastatic tumor cells in a sample containing the tumor cells and hematopoietic cells.
The invention also relates to kits for carrying out these processes and to the cell preparations prepared by the processes.

Claims (32)

1. An antibody composition comprising antibodies specific for glycophorin A, CD3 CD24, CD16, CD14, non-hematopoietic antigens expressed on tumor cells, and optionally one or more antibodies specific for CD45RA, CD38, CD36, CD56, CD2, CD19, CD66e, and CD66b.
2. An antibody composition comprising antibodies specific for glycophorin A, CD3, CD24, CD16, CD14, CD56, CD2, CD19, and CD66b. and optionally antibodies specific for non-hematopoietic antigens.
3. An antibody composition as claimed in claim 1 or 2, wherein the antibodies are monoclonal antibodies.
4. An antibody composition as claimed in claim 1, 2, or 3 wherein the antibodies are labelled with a marker or they are directly or indirectly conjugated to a matrix.
5. An antibody composition as claimed in claim 1, 2, 3, or 4 wherein the antibodies are labelled with biotin or a fluorochrome.
6. An antibody composition as claimed in claim 5 wherein the matrix is magnetic beads, a panning surface, dense particles for density centrifugation, an adsorption column, or an adsorption membrane.
7. An antibody composition as claimed in claim 2 wherein each of the monoclonal antibodies is incorporated in a tetrameric antibody complex which comprises a first monoclonal antibody of a first animal species from the antibody composition as claimed in claim 2, and a second monoclonal antibody of the first animal species which is capable of binding to at least one antigen on the surface of a matrix, which have been conjugated to form a cyclic tetramer with two monoclonal antibodies of a second animal species directed against the Fc-fragments of the antibodies of the first animal species.
8. An antibody composition as claimed in claim 1, consisting of (a) antibodies specific for glycophorin A, CD3, CD24, CD16, CD14, CD19, CD66b, CD56 and CD2; or (b) antibodies specific for glycophorin A, CD3, CD24, CD16, CD14, CD19, CD66b, CD56, CD2, CD36, CD38, and CD45RA.
9. An antibody composition as claimed in claim 1, consisting of antibodies specific for glycophorin A, CD3, CD24, CD16, CD14, CD19, CD66b, CD56, CD2, CD36, CD38, CD45RA, and for non-hematopoietic antigens expressed on tumor cells.
10. An antibody composition as claimed in claim 9 which contains antibodies specific for antigens on the surface of cells from breast or lung carcinoma, or neuroblastoma.
11. An antibody composition as claimed in claim 10 which comprises D2.10 or 10F7MN, UCHT1, 6F10.3, T199, J4119, MEM15, 3G8 or MEM154, 80H3 or B13.29, FA6.152 or IVC7, AD2.2, T16, J33, 5E11, H23A, 6E7, RAR, and BRST1.
12. A process for enriching and recovering human hematopoietic progenitor cells and stem cells in a sample containing human hematopoietic stem cells, and tumor cells comprising reacting the sample with an antibody composition containing antibodies capable of binding to the antigens glycophorin A, CD3 CD24, CD16, and CD14, and optionally CD45RA, CD38, CD36, CD56, CD2, CD19, CD66e, and/or CD66b, and antibodies specific for non-hematopoietic antigens expressed on tumor cells, under conditions so that cell conjugates are formed between the antibodies and cells in the sample containing the antigens glycophorin A, CD3 CD24, CD16, and CD14, and optionally CD19, CD20, CD56, CD2, CD19, CD66e, and/or CD66b and non-hematopoietic antigens on their surfaces; removing the cell conjugates; and, recovering a cell preparation which is enriched in human hematopoietic progenitor cells and stem cells.
13. A process as claimed in claim 12 wherein the antibody composition consists of antibodies specific for glycophorin A, CD3, CD24, CD16, CD14, CD19, CD66b, CD56, CD2, CD36, CD38, Cd45RA, and for non-hematopoietic antigens expressed on tumor cells.
14. A process as claimed in claim 12 or 13, wherein the antibodies in the antibody composition are monoclonal antibodies.
15. A process as claimed in claim 12, wherein the antibodies in the antibody composition are labelled with a marker or they are conjugated to a matrix.
16. A process as claimed in claim 12, wherein the antibodies in the antibody composition are labelled with biotin or a fluorochrome.
17. A process as claimed in claim 12 wherein the matrix is magnetic beads, a panning surface, dense particles for density centrifugation, an adsorption column, or an adsorption membrane.
18. A process as claimed in claim 14, wherein each of the monoclonal antibodies in the antibody composition is incorporated in a tetrameric antibody complex which comprises a first monoclonal antibody of a first animal species from the antibody composition as claimed in claim 2, and a second monoclonal antibody of the first animal species which is capable of binding to at least one antigen on the surface of a matrix, which have been conjugated to form a cyclic tetramer with two monoclonal antibodies of a second animal species directed against the Fc-fragments of the antibodies of the first animal species.
19. A process as claimed in claim 12 wherein the tumor cells are from a breast or lung carcinoma, or neuroblastoma, and the antibody composition contains antibodies specific for antigens expressed on the surface of cells from breast or lung carcinoma, or neuroblastoma.
20. A process as claimed in claim 19 wherein the tumor cells are from a breast carcinoma, and the antibody composition contains one or more of the antibodies designated 5E11, H23A, 6E7, RAR, and BRST1.
21. A kit useful in performing the process as claimed in claim 12 comprising antibodies specific for glycophorin A, CD3, CD24, CD16, CD14, and for non-hematopoietic antigens expressed on tumor cells, and optionally CD45RA, CD38, CD36, CD38, CD56, CD2, CD19, CD66e, CD66b, and instructions for performing the process.
22. Cell compositions obtained in accordance with the process as claimed in claim 12.
23. Use of an antibody composition as claimed in claim 1 in a negative selection technique to recover cell preparations enriched in human hematopoietic progenitor and stem cells.
24. An antibody composition comprising antibodies specific for glycophorin A, CD3, CD19, CD36, CD14, CD16, CD66b, CD56, CD38, CD36, CD45, and optionally CD41, CD33, CD20, CD22, CD29, CD2, CD45RA, and/or CD10.
25. An antibody composition as claimed in claim 24, wherein the antibodies are monoclonal antibodies.
26. An antibody composition as claimed in claim 25 wherein the antibodies are labelled with a marker or they are directly or indirectly conjugated to a matrix.
27. An antibody composition as claimed in claim 26 wherein the antibodies are labelled with biotin or a fluorochrome.
28. An antibody composition as claimed in claim 26 wherein the matrix is magnetic beads, a panning surface, dense particles for density centrifugation, an adsorption column, or an adsorption membrane.
29. An antibody composition as claimed in claim 26 wherein each of the monoclonal antibodies is incorporated in a tetrameric antibody complex which comprises a first monoclonal antibody of a first animal species from the antibody composition as claimed in claim 25, and a second monoclonal antibody of the first animal species which is capable of binding to at least one antigen on the surface of a matrix, which have been conjugated to form a cyclic tetramer with two monoclonal antibodies of a second animal species directed against the Fc-fragments of the antibodies of the first animal species.
30. A process for enriching for non-hematopoietic metastatic tumor cells in a sample containing the tumor cells and hematopoietic cells comprising (a) reacting the sample with an antibody composition comprising antibodies specific for glycophorin A, CD3, CD19, CD36, CD14, CD16, CD66b, CD56, CD38, CD36, CD45, and optionally CD41, CD33, CD20, CD22, CD29, CD2, CD45RA, and/or CD10. under conditions so that conjugates are formed between the antibodies and hematopoietic cells in the sample expressing the antigens glycophorin A, CD3, CD19, CD36, CD14, CD16, CD66b, CD56, CD38, CD36, CD45, and optionally CD41, CD33, CD20, CD22, CD29, CD2, CD45RA, and/or CD10;
(b) removing the cell conjugates, and (c) recovering a cell preparation enriched in the tumor cells.
31. A process for detecting non-hematopoietic metastatic tumor cells in a sample comprising (a) reacting the sample with an antibody composition comprising antibodies specific for glycophorin A, CD3, CD19, CD36, CD14, CD16, CD66b, CD56, CD38, CD36, CD45, and optionally CD41, CD33, CD20, CD22, CD29, CD2, CD45RA, and/or CD10 under conditions so that conjugates are formed between the antibodies and hematopoietic cells in the sample expressing the antigens glycophorin A, CD3, CD19, CD36, CD14, CD16, CD66b, CD56, CD38, CD36, CD45, and optionally CD41, CD33, CD20, CD22, CD29, CD2, CD45RA, and/or CD10;
(b) removing the cell conjugates; and (c) recovering a cell preparation enriched in the tumor cells.
32. A kit useful in performing a process as claimed in claim 30 or 31 comprising antibodies specific for glycophorin A, CD3, CD19, CD36, CD14, CD16, CD66b, CD56, CD38, CD36, CD45, and optionally CD41, CD33, CD20, CD22, CD29, CD2, CD45RA, and/or CD10, and instructions for performing the process as claimed in claim 29 or 30.
CA002191655A 1995-12-01 1996-11-29 Novel antibody compositions for preparing enriched human hematopoietic and tumor cell preparations Expired - Lifetime CA2191655C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/566,295 US6306575B1 (en) 1995-06-16 1995-12-01 Methods for preparing enriched human hematopoietic cell preparations
US08/566,295 1995-12-01

Publications (2)

Publication Number Publication Date
CA2191655A1 true CA2191655A1 (en) 1997-06-02
CA2191655C CA2191655C (en) 2010-01-12

Family

ID=24262300

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002191655A Expired - Lifetime CA2191655C (en) 1995-12-01 1996-11-29 Novel antibody compositions for preparing enriched human hematopoietic and tumor cell preparations

Country Status (1)

Country Link
CA (1) CA2191655C (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000072010A1 (en) * 1999-05-19 2000-11-30 Eberhard-Karls-Universität Tübingen Universitätsklinikum Use of an antibody to detect basophiles and/or mast cells
WO2001011011A3 (en) * 1999-08-05 2001-05-10 Leo T Furcht Multipotent adult stem cells and methods for isolation
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US7838289B2 (en) 2001-02-14 2010-11-23 Abt Holding Company Assay utilizing multipotent adult stem cells
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
US8426200B2 (en) 2003-07-02 2013-04-23 Regents Of The University Of Minnesota Neuronal differentiation of stem cells
US8609412B2 (en) 1999-08-05 2013-12-17 Regents Of The University Of Minnesota Mapc generation of lung tissue
US9005964B2 (en) 2006-11-24 2015-04-14 Regents Of The University Of Minnesota Endodermal progenitor cells
CN110023736A (en) * 2016-10-17 2019-07-16 圣拉斐尔医院有限责任公司 For identifying purposes, method, kit, composition and the antibody of hematopoietic cell hypotype
US10638734B2 (en) 2004-01-05 2020-05-05 Abt Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000072010A1 (en) * 1999-05-19 2000-11-30 Eberhard-Karls-Universität Tübingen Universitätsklinikum Use of an antibody to detect basophiles and/or mast cells
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US7659118B2 (en) 1999-08-05 2010-02-09 Abt Holding Company Multipotent adult stem cells
EP2348104A1 (en) * 1999-08-05 2011-07-27 Mcl Llc Multipotent adult stem cells and methods for isolation
WO2001011011A3 (en) * 1999-08-05 2001-05-10 Leo T Furcht Multipotent adult stem cells and methods for isolation
US8609412B2 (en) 1999-08-05 2013-12-17 Regents Of The University Of Minnesota Mapc generation of lung tissue
US10226485B2 (en) 1999-08-05 2019-03-12 Abt Holding Company Multipotent adult stem cells and methods for isolation
US7838289B2 (en) 2001-02-14 2010-11-23 Abt Holding Company Assay utilizing multipotent adult stem cells
US8426200B2 (en) 2003-07-02 2013-04-23 Regents Of The University Of Minnesota Neuronal differentiation of stem cells
US10638734B2 (en) 2004-01-05 2020-05-05 Abt Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US9005964B2 (en) 2006-11-24 2015-04-14 Regents Of The University Of Minnesota Endodermal progenitor cells
CN110023736A (en) * 2016-10-17 2019-07-16 圣拉斐尔医院有限责任公司 For identifying purposes, method, kit, composition and the antibody of hematopoietic cell hypotype

Also Published As

Publication number Publication date
CA2191655C (en) 2010-01-12

Similar Documents

Publication Publication Date Title
CA2346362A1 (en) Novel antibody compositions for preparing enriched mesenchymal progenitor preparations
CA2178984A1 (en) Novel antibody compositions for preparing enriched human hematopoietic cell preparations
US6306575B1 (en) Methods for preparing enriched human hematopoietic cell preparations
US6117985A (en) Antibody compositions for preparing enriched cell preparations
EP1185867B1 (en) Method for separating cells using immunorosettes
JP2003501629A5 (en)
US5814440A (en) Methods of obtaining compositions enriched for hematopoietic stem cells, antibodies for use therein, compositions derived therefrom and methods of use thereof
CA2279474A1 (en) Novel antibody composition for debulking blood and bone marrow samples from cml patients
CA2191655A1 (en) Novel antibody compositions for preparing enriched human hematopoietic and tumor cell preparations
CA2279476A1 (en) Novel antibody composition for isolating human cells from human-murine chimeric hematopoietic cell suspensions
GR3036951T3 (en) Cells with multiple altered epitopes on a surface antigen for use in transplantation
JPH0361480A (en) Dissociation of cell from affinity matrix
US20020081635A1 (en) Novel antibody compositions for preparing enriched T cell preparations
JPH05504059A (en) Isolation method for hematopoietic progenitor cells
Orlic et al. Pluripotent hematopoietic stem cells of low and high density can repopulate W/Wv mice
Berenson et al. Selection of CD34+ marrow cells for autologous marrow transplantation
CA2347439A1 (en) Novel antibody compositions for preparing enriched eosinophil preparations
EP0204522A3 (en) Monoclonal antibody panel for histocompatibility typing
SILVESTRI et al. Positive Selection of CD34+ Cells: A Short Review of the Immunoadsorption Methods Currently Available for Experimental and Clinical Use: Report on the" 2nd European Workshop on Stem Cell Methodology," Mulhouse, France, May 3-7, 1993
CA2936914A1 (en) Method for separating target entities from a sample using a composition of mono-specific tetrameric antibody complexes coupled to a surface
US20020155511A1 (en) Novel antibody compositions for the negative selection of specific rat leukocyte subsets
EP0356397A3 (en) Monoclonal antibodies against, and cell surface antigen of, lung carcinoma
Long et al. Chromatographic and electrophoretic analysis of an antigen in Hodgkin's disease tissue cultures
Frickhofen et al. Enrichment of hematopoietic progenitor cells from human bone marrow on Percoll density gradients
Poels et al. Common and specific antigens on two tumor cell lines

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20161129